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A simple and robust method for connecting small-molecule drugs using
gene-expression signatures
Shu-Dong Zhang∗ and Timothy W. Gant
MRC Toxicology Unit, Hodgkin Building, Lancaster Road, University of Leicester, Leicester, UK
Interaction of a drug or chemical with a biological system can result in a gene-expression profile
or signature characteristic of the event. Using a suitably robust algorithm these signatures can
potentially be used to connect molecules with similar pharmacological or toxicological properties.
The Connectivity Map was a novel concept and innovative tool first introduced by Lamb et al to
connect small molecules, genes, and diseases using genomic signatures [Lamb et al (2006), Science
313, 1929-1935]. However, the Connectivity Map had some limitations, particularly there was
no effective safeguard against false connections if the observed connections were considered on
an individual-by-individual basis. Further when several connections to the same small-molecule
compound were viewed as a set, the implicit null hypothesis tested was not the most relevant one
for the discovery of real connections. Here we propose a simple and robust method for constructing
the reference gene-expression profiles and a new connection scoring scheme, which importantly
allows the valuation of statistical significance of all the connections observed. We tested the new
method with the two example gene-signatures (HDAC inhibitors and Estrogens) used by Lamb et
al and also a new gene signature of immunosuppressive drugs. Our testing with this new method
shows that it achieves a higher level of specificity and sensitivity than the original method. For
example, our method successfully identified raloxifene and tamoxifen as having significant anti-
estrogen effects, while Lamb et al’s Connectivity Map failed to identify these. With these properties
our new method has potential use in drug development for the recognition of pharmacological and
toxicological properties in new drug candidates.
I. INTRODUCTION
One of the most fundamental challenges in all forms
of ’omic technologies is the connection of biological event
signatures with others previously derived to allow the
recognition of new molecule properties or biological al-
teration. Simple, robust, and efficient matching methods
are required to connect a new gene signature with those
in a database. This problem was first tackled by Lamb
et al [1] who introduced the Connectivity Map as a re-
source and tool to connect small-molecule drugs, genes,
and diseases. Lamb et al’s Connectivity Map achieved
a good degree of success, but also suffered from several
deficiencies, particularly an inability to apply a measure
of statistical validity at the individual reference signature
level to allow rational filtering of the results to exclude
false connections. We took the method of Lamb as a basis
for development and have derived a simple, robust and
statistically testable method for making connections be-
tween biological event signatures. The method was tested
with genomic signatures resulting from small molecule in-
teractions in cells, but also could be applied to any form
of signature such as those from proteomic or metabolomic
science.
The main assumption behind the concept of Connec-
tivity Map is that a biological state, whether physio-
logical, pathological, or induced with chemical or ge-
nomic perturbations, can be described in terms of a ge-
nomic signature, eg., the genome-wide mRNA levels as
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measured by DNA microarray technologies. The work-
ing of the Connectivity Map involves several key com-
ponents. First, a large collection of pre-built reference
gene-expression profiles serve as the core database, where
each reference profile characterizes a well-defined biolog-
ical state. Secondly, a query gene signature from some
specific studies. A query gene signature is basically a
short (as compared to the list of genes in a typical refer-
ence profile) list of genes most relevant and important to
characterize the biological state of the researchers’ inter-
est. Finally, a pattern matching algorithm or similarity
metric defined between a query gene signature and a ref-
erence gene-expression profile to quantify the closeness or
connection between the two biological states. The Con-
nectivity Map could be used by biomedical researchers to
find connections between the reference biological states
and those of their own interest. This may lead to new
findings of unexpected connections and testable new bi-
ological hypotheses. In this paper, we present a new
framework for the construction of reference profiles and
new connection scoring scheme and testing procedures
for the observed connections. We compare our method
with that of Lamb et al, and show that more robust re-
sults are achieved using our method. In particular our
method not only offers more principled statistical pro-
cedures for testing connections, but more importantly
it provides effective safeguard against false connections
while at the same time achieves much increased sensi-
tivity. As a consequence it can benefit the end users by
saving them enormous amount of time and resources in
pursuing new biological hypotheses based on the findings
of connectivity maps.
2II. METHODS
A. Construction of reference profiles
For the first-generation connectivity map, Lamb et
al carried out a series of gene-expression profiling ex-
periments [1], using 164 distinct small-molecule com-
pounds in a few selected human cell lines. Each treat-
ment instance consisted of one treatment sample and one
(or more) vehicle control samples, whose genome wide
mRNA levels were measured using Affymetrix GeneChip
microarrays. In total 564 samples were microarrayed,
which represented 453 different treatment instances. For
example, treatment instance ID988 consisted of 1 treat-
ment sample and 6 vehicle control samples. The treat-
ment sample was obtained by treating human MCF7 cells
with 100nM estradiol for 6 hours. The control samples
were obtained by treating MCF7 cells with vehicle control
for 6 hours. A gene-expression profile was constructed for
each treatment instance, in which the relative expression
(treatment relative to the control) of all measured genes
were specified, and sorted in descending order. A query
gene signature, obtained and ordered in the same man-
ner, can be compared to each reference profile in the Con-
nectivity Map to calculate a connectivity score. For “pos-
itive connectivity”, the up-regulated genes of the query
signature find matches near the top of the reference pro-
file, and the down-regulated genes find matches near the
bottom of the reference profile. For “negative connectiv-
ity”, the matches are opposite.
We obtained Lamb et al’s data set (Accession Number
GSE5258) from the GEO (Gene Expression Omnibus)
database, and rebuilt 453 reference gene-expression pro-
files using a new ranking scheme based on the follow-
ing guiding principles: (1) A treatment instance was de-
fined relative to a control, thus the effect of the treat-
ment could be characterized by the relative differential
expression status of all the genes together, (2) different
genes were affected to different extents by the treatment,
so genes which showed a greater differential expression
should have more weight in characterizing this treatment,
and (3) up- and down-regulated genes should be treated
equally in a unified manner. This meant that a 2-fold
down-regulated gene was considered as equally impor-
tant as a 2-fold up-regulated gene in defining a reference
profile. There are several reasons for the choice of treat-
ing up- and down-regulated genes equally. Theoretically,
unless we have a lot of further information about so many
genes on the microarray it is difficult to decide whether
this 2-fold up-regulated gene is more important than that
2-fold down-regulated gene or the opposite. So a logical
choice is to assign them equal weights. Another reason
is the consideration of symmetry: if a gene is 2-fold up-
regulated in sample 1 versus sample 2, it can also be
viewed as 2-fold down-regulated in sample 2 versus sam-
ple 1. We should emphasize that assigning two genes
equal weights does not imply in any sense they share
the same molecular mechanism. Even two up-regulated
genes with the same fold changes could have very differ-
ent molecular mechanisms as to why they increased their
expression. To adhere to the above guidelines, an obvious
choice for organizing the genes is the logarithm of the ex-
pression ratio (treatment over control). Thus instead of
treating the down- and up-regulated genes separately as
in the methods of Lamb et al, we ordered genes in a refer-
ence profile by the absolute value of their expression log-
ratios. Therefore the most differentially expressed genes
(either up or down) appear first in the list, and those
non-differentially expressed genes appear at the bottom
of the list. In this way, the genes are ordered by their
importance in defining the reference profile. It is then
straightforward to assign ranks to them. Suppose there
are in total N genes, the first gene in the list will be as-
signed a rank N if it is up-regulated, or a rank −N if it is
down-regulated. In general the ith gene in the list will be
ranked with (N − i+1) for up-regulation or −(N − i+1)
for down-regulation. With this new ranking method, the
importance of a gene is reflected by the absolute value of
its rank, while the sign of its rank indicates its regulation
status. The consequence and advantage of this method
for creating reference profiles is that attaching statisti-
cal significance to the connection observed is a relatively
straightforward step.
B. The new scoring scheme
A query gene signature can be an ordered gene list,
or just a collection of genes without specific ordering
among them. We will refer to these two types of query
gene signatures as ordered and unordered gene signature
respectively. For an ordered gene signature, we rank
the genes in the list in the same way as for a reference
profile. Namely, the most important (differentially ex-
pressed) gene in the signature will be assigned a rank m
or −m depending on its regulation status, where m is
the number of genes in the signature. While the least
important gene in the signature be ranked 1 or −1.
Let R denote a reference gene-expression profile, and s
a query gene signature. We define the connection strength
between R and s as
C(R, s) =
m∑
i=1
R(gi)s(gi), (1)
where gi represents the ith gene in the signature, s(gi) is
its signed rank in the signature, and R(gi) is this gene’s
signed rank in the reference profile. It is worth not-
ing some properties of the connection strength defined
above: (1) if a gene has the same regulation status (ei-
ther up- or down-regulation) in both the reference and
the query, it will make a positive contribution to the
connection strength, otherwise its contribution will be
negative; (2) the magnitude of a gene’s contribution to
the connection strength is determined by its position in
both lists; and (3) a gene signature with some of its genes
3contributing positively and others negatively will have an
overall low connection strength, because the positive and
negative contributions cancel each other to some extent.
Therefore calculating the connection strength between a
gene signature and a reference profile, the maximum con-
nection strength achievable is the situation where the m
genes in the signature match the first m genes in the ref-
erence profile in the correct order, and their regulation
status also match. In such a case, the maximum positive
connection strength is, for an ordered gene signature,
Co
max
(N,m) =
m∑
i=1
(N − i + 1)(m− i+ 1). (2)
In another equally interesting situation, where the m
genes in the signature match the first m genes in the
reference profile in the right order, but the sign of each
gene in the query is different from its sign in the reference,
the connection strength is −Co
max
(N,m), the opposite of
Eq.(2).
For an unordered query signature, all the genes in
the list have equal weight because there is no particu-
lar ordering among them. The calculation of connection
strength is the same as Eq.(1), the only difference being
that s(gi) = 1 if gene gi is up-regulated, or s(gi) = −1 if
it is down-regulated. Consequently, the maximum mag-
nitude of connection strength for an unordered signature
is
Cu
max
(N,m) =
m∑
i=1
(N − i+ 1). (3)
Given a query signature gene and a reference gene-
expression profile, we can calculate their connection score
by
c = C(R, s)/Cmax(N,m). (4)
So a connection score c = 1 means that the gene signature
has the maximum positive connection strength with the
reference profile, which indicates that the experimental
condition that gave rise to this gene signature had the
strongest possible correlation with the treatment instance
that generated the reference profile. A connection score
c = −1 indicates that the two experimental perturbations
were most inversely correlated. In general, a connection
score c will be within the range of (−1, 1).
C. Connection Testing
As for most biomedical experiments with unavoidable
biological and technical variation, statistical significance
is a crucial aid to the interpretation and subsequent val-
idation of the result. Here we propose calculating the
p-value associated with a connection score by testing the
following null hypothesis.
Null hypothesis H0: For a reference gene-expression
profile R and a query gene signature s, the null hypoth-
esis H0 states that there is no underlying biological con-
nection between the two, and that the query signature
s is merely a random m-gene signature, as generated by
Procedure 1 described below.
Procedure 1: Generation of a random m-gene signa-
ture. Let R be a given reference gene-expression profile
of N genes. Select m genes sequentially and randomly
from the N genes (without replacement), and assign +1
(up-regulation) or −1 (down-regulation) randomly with
equal probability to each of the m selected genes. If this
gene signature is to be used as an ordered list, its order
is just the order in which the m genes are selected; or if
this gene signature is to be used as merely a collection of
genes, then order is irrelevant.
Given a reference profile R and a gene signature s, we
calculate their connection score c by Eq.(4), and the two-
tailed p-value associated with this observed connection
score is
p = Prob {|c˜| ≥ |c| | H0} , (5)
where c˜ is the connection score between a random gene
signature and the reference profile. To estimate the p-
value, a large number (eg., 105) of random connection
scores can be generated using Procedure 1 and Eq.(4),
the proportion of random scores that are no less than
the observed scores c in absolute value is an estimate of
the two-tailed p-value.
The 453 individual treatment instances of the data
set GSE5258 were created using only 164 distinct small-
molecule compounds. Some treatment instances were
replication experiments using the same compound at the
same or different doses. It is thus interesting to consider
all the treatment instances of the same compound as a
set, and to assess the overall connection of the set with
a query gene signature. We define the connection score
for a treatment set as follows
t =
1
n
n∑
i=1
ci, (6)
where n is the number of individual treatment instances
belonging to the treatment set, ci is the connection score
of the ith instance. To test the significance of a treatment
set as a whole. We used the following null hypothesis,
Null hypothesis Hset
0
: Where T denotes a set of
treatment instances, Ri the reference profile based on
treatment instance i, and s a query gene signature, the
null hypothesis Hset
0
states that there is no underlying
biological connection between the gene signature s and
any of the reference profiles in T. The query signature is
merely a random gene list generated by Procedure 1.
Thus the null hypothesis Hset
0
is an extension of H0
to a higher level. Alternatively, H0 can be viewed as a
special case of Hset
0
, in which there is only one treat-
ment instance in the treatment set. Once the connection
score for a set is observed, its associated p value can
4TABLE I: The connectivity scores of the random gene signa-
ture rds01 to the reference profiles in the Lamb Connectivity
Map.
rank ID compound score up down
1 1080 sirolimus 1 0.232 -0.578
2 913 colforsin 0.953 0.245 -0.527
3 1138 phentolamine 0.912 0.316 -0.423
4 1048 alpha-estradiol 0.886 0.324 -0.394
5 1115 phenanthridinone 0.869 0.379 -0.325
· · · · · · · · · · · · · · · · · ·
112 885 5186223 0.363 0.137 -0.157
113 3 metformin 0.342 0.158 -0.119
114 663 U0125 0 0.405 0.194
115 124 mesalazine 0 0.371 0.256
· · · · · · · · · · · · · · · · · ·
369 1008 geldanamycin 0 -0.43 -0.339
370 1064 17AAG 0 -0.436 -0.395
371 605 monastrol -0.38 -0.114 0.177
372 494 fluphenazine -0.392 -0.113 0.187
· · · · · · · · · · · · · · · · · ·
449 601 MK-886 -0.834 -0.303 0.336
450 604 arachidonic acid -0.855 -0.301 0.354
451 387 estradiol -0.901 -0.162 0.528
452 379 cobalt chloride -0.916 -0.238 0.464
453 378 tacrolimus -1 -0.23 0.536
be estimated in a similar way: a large number of random
gene signatures are generated using Procedure 1, and the
connection score of the set to each of the random gene
signatures is calculated using Eq.(6); the proportion of
random connection scores that are greater than the ob-
served score in absolute value is an estimation of the p
value.
III. RESULTS
A. Querying the connectivity maps with random
gene signatures
To compare the specificities of Lamb et al’s Connectiv-
ity Map and the connectivity map presented here, we gen-
erated random gene signatures and tested these random
gene signatures in both. The first example was a random
gene signature, rds01, which contained 25 Affymetrix
probe-set IDs randomly selected from the 22283 IDs on
the Affymetrix HG-U133A microarray platform. Query-
ing Lamb et al’s Connectivity Map with this signature,
we obtained the connectivity scores of rds01 to all the 453
individual treatment instances. The results are shown in
Table I, which suggests that this signature has positive
connections to 113 individual reference profiles, with con-
nectivity scores ranging from 1 to 0.342; and that 83 indi-
vidual reference profiles have negative connections with
rds01, with connectivity scores ranging from−1 to −0.38;
the remaining 257 reference profiles have null connections
(connectivity score 0). However rds01 was a random gene
signature and so all these positive and negative connec-
tions must be false. We then used this same random sig-
nature to query the connectivity map presented in this
paper (Table II). With a p value calculated for each
observed connection score, we can control the expected
number of false connections by setting an appropriate
threshold p value. In this paper, the threshold p value
is generally set at 1/N , where N is the number of null
hypotheses being tested simultaneously. In this exam-
ple, N = 453 (the total number of individual treatment
instances in the database and hence the number of null
hypothesis being tested at the treatment instance level).
So a connection with a p value p < 1/453 = 0.0022 is
considered as statistically significant. The setting of the
threshold p value at 1/N was intended to control the
expected number of false connections at 1, we thus ex-
pected to have one false connection on average among all
the connections declared as significant. Table II shows
that our connectivity map gave the correct result, ie.,
no significant connection between this random signature
and any of the treatment instances. This compares with
the 196 connections (113 positive and 83 negative) found
with the method of Lamb et al. Note that to control the
expected number of false connections more precisely, the
threshold hold p value should be set at 1/N0, where N0
is the number of true null hypothesis. Of course in a gen-
eral situation N0 is unknown, so it has to be estimated,
for example, using the methods developed in [2, 3]. In
this paper, we set threshold p value at 1/N for simplicity.
Since N0 ≤ N , our criteria tend to be slightly conserva-
tive, meaning that the actual number of false connections
on average will be ≤ 1.
The second random gene signature, rds02, consisted
of 189 Affymetrix probe-set IDs randomly selected from
22283. The full results of querying Lamb et al’s Con-
nectivity Map with this signature can be found in the
supplementary data, which suggests that rds02 has posi-
tive connections to 107 reference profiles, and negative
connections to 119 profiles. However once again we
know these must be all false connections. Conversely,
the new method presented in this paper gave results
that agree with the underlying truth. With the crite-
ria set above there was 1 connection found significant
(p < 1/453 = 0.0022). Since we expect on average 1 false
connection, this declared significant connection can be
taken as false.
The two examples of random gene signatures above
revealed that on the individual treatment instance level
Lamb et al’s Connectivity Map gave many false connec-
tions because no safeguard was provided for these. The
reason for this was in the way the connectivity scores were
calculated. Briefly, Lamb et al’s connectivity score was
based on the Kolmogorov-Smirnov statistic. At first two
K-S statistics were calculated, one for the up-regulated
genes, and one for the down-regulated, then these two
5TABLE II: The connection scores for the random gene signa-
ture rds01 using the new methods. To control the expected
number of false connections at 1, the threshold p value was set
at 1/453 = 0.0022. No connection was found to be significant,
which agrees with the underlying truth.
rank Compound ID score pvalue
1 (-)-catechin 1101 0.334 0.003
2 sirolimus 1022 0.312 0.006
3 phentolamine 1138 0.309 0.007
4 5162773 892 0.292 0.011
5 resveratrol 595 0.286 0.013
· · · · · · · · · · · ·
451 felodipine 848 -0.002 0.988
452 estradiol 988 -0.001 0.991
453 bucladesine 959 0.001 0.993
values were combined to give a single connectivity score.
This way of defining the connection score was unneces-
sarily complex, which made the calculation of a possible
p-value on an individual level difficult, if not impossible.
On the treatment set level, Lamb et al’s Connectivity
Map provides a permutation p value when a set of treat-
ment instances associated with the same compound were
viewed as a whole. The permutation p value was calcu-
lated by comparing a statistic (again based on K-S statis-
tic) of the treatment set with the distribution of many
random-set statistics. Those random sets were formed
by randomly selecting treatment instances from all in-
stances. From the way the permutation p value was cal-
culated, it was clear that the following null hypothesis
was being tested: The set of instances in question have
the same pattern (distribution) of connections with the
query gene signature compared with a randomly formed
set of the same size. A null hypothesis such as this is not
the most appropriate one to test, because it is not di-
rectly relevant to the question of whether the query gene
signature had any real biological connection to the treat-
ment set. Lamb et al themselves also recognized that
more rigorous methods for the estimation of statistical
significance were probably required[1]. Putting its appro-
priateness aside, if we do use the permutation p values
from Lamb et al’s Connectivity Map to control false con-
nections, the same criteria for setting threshold p value
can be used. The results of significance analysis on the
connections between the two random gene signatures and
the 164 treatments sets can be found in the supplemen-
tary data. In this instance both connectivity maps gave
the right answers for these two random gene signatures.
However, for Lamb et al’s Connectivity Map permutation
p values were not available for all the 164 treatment sets.
For those treatment sets which only contain 1 treatment
instance or those sets with mean connectivity score 0, no
permutation p values could be calculated, and hence no
statistical significance. This problem affects the coverage
and consequently the sensitivity of Lamb et al’s Connec-
tivity Map, because real biological connections between
FIG. 1: HDAC inhibitor gene signature: The Venn diagram
summarizing the findings of significant connections as identi-
fied by the connectivity maps. A represents the instance-level
analysis using the new method; B, the set-level analysis using
the new method; C, the set-level analysis using Lamb et al’s
Connectivity Map. The label “AB 13” means that 13 com-
pounds are identified as significant solely by A and B (not
C), “B 4” means that 4 compounds are identified as signif-
icant solely by B (not A, not C), and so on. The areas are
approximately proportional to the numbers they represent.
a query gene signature and any of those treatment sets
may not be recognized.
B. Querying the connectivity maps with
experimentally derived real gene signatures
1. HDAC inhibitors
To test the ability of the new method for identifying
real biological connections we utilized some of the same
examples used in [1] to compare with Lamb et al’s Con-
nectivity Map. The first example was a gene signature
of histone deacetylase (HDAC) inhibitors (Lamb’s gene
signature sigs01), which was compiled from [4] on the re-
sponses of T24, MDA435 and MDA468 cells respectively
to three histone deacetylase (HDAC) inhibitors: vorino-
stat, MS-27-275, and trichostatin A. This gene signature
consisted of 8 up- and 5 down-regulated genes, repre-
sented by 25 Affymetrix probe-set IDs on the Affymetrix
HG-U133A microarrays.
As Lamb et al’s Connectivity Map does not provide
any safeguard on individual treatment instance level
against possible false connections, we can only use the
results of Lamb et al’s Connectivity Map on the treat-
ment set level. In total 6 compounds (vorinostat, tricho-
statin A, resveratrol, geldanamycin, valproic acid, and
17AAG) were identified to have significant positive con-
nectivity with the HDAC inhibitor gene signature; and
2 compounds (5182598 and fludrocortisone) had signif-
icant negative connectivity. Vorinostat, trichostatin A,
and valproic acid are known HDAC inhibitors thus the
identification of these can be regarded as a success. How-
6ever another known HDAC inhibitor HC-toxin, a refer-
ence profile of which was contained in the database, was
not identified. This happened because there was only
one treatment instance of the compound HC-toxin in the
database and so no permutation p value could be ob-
tained using Lamb et al’s method. Based on their in-
stance level results, Lamb et al highlighted HC-Toxin in
[1] as it had the 7th highest connectivity score (0.914)
of all instances in the dataset. However, as the two ex-
amples of random gene signatures showed Lamb et al’s
instance level analysis gave false connections even for the
highest connectivity scores 1.0. So the rational choice is
to disregard the instance level results from Lamb et al’s
Connectivity Map.
We used this same HDAC inhibitor gene signature to
query the new connectivity map presented here, with p
values calculated at both the individual instance level
and the treatment set level. 56 treatment instances, rep-
resenting 22 distinct compounds, were found to have sig-
nificant connections to sigs01. On the treatment set level
24 compounds were found to have significant connec-
tions with the signature. Near the top of the significant
connection list were those known HDAC inhibitors high-
lighted in [1]. Importantly though also included in the
output was HC-Toxin, which was not identified by the
set-level analysis Lamb et al’s Connectivity Map. The
full results of querying both connectivity maps using the
HDAC inhibitor gene signature are included in the sup-
plementary data. In Fig. 1, we summarize the number
of significant connections as identified by: (A) Instance
level analysis using the new method presented here; (B)
Set level analysis using the new method; (C) Set level
analysis using Lamb et al’s Connectivity Map. In total,
our method (A) and (B) combined identified 27 com-
pounds and Lamb et al’s Connectivity Map identified
8 compounds, as having significant connections to the
HDAC inhibitors. Our method missed only 1 of the 8
compounds found significant by Lamb et al’s Connectiv-
ity Map, while the latter missed 20 of the 27 compounds
identified by our method, with HC-toxin among the 20
compounds that were missed. The HDAC inhibitors ex-
ample thus shows that our new method is more sensitive
at detecting real connections. With the increased sen-
sitivity and false connections being properly controlled,
the potential benefit of our method is obvious. In this
example, the set-level analysis of Lamb et al’s Connec-
tivity Map identified 8 compounds with a false discovery
rate of 12.5% (1/8), while the set-level analysis using our
method identified 24 compounds with a false discovery
rate of 4.2% (1/24). Based on the findings of the connec-
tivity maps, researchers can prioritize a small sub set of
those compounds for further investigations and/or devel-
oping new biological hypotheses. For this example, using
Lamb et al’s Connectivity Map, the chance of pursuing
a false connection is 12.5%, while using our method it
is much lower at 4.2%. In practice this would save the
researchers an enormous amount of time and resources
and increase their rate of success.
2. Estrogens
The second example was a gene signature (Lamb’s gene
signature sigs02) taken from a study [5] of MCF7 cells
treated with estradiol. This gene signature consisted of
40 up- and 89 down-regulated genes represented by 189
Affymetrix probe-set IDs on the Affymetrix HG-U133A
microarrays. We queried both Lamb et al’s Connectivity
Map and the connectivity map presented in this paper
with this estrogen signature.
For the same reason given above, we only used the
treatment set level results of Lamb et al’s Connectivity
Map, which identified 4 compounds (genistein, estradiol,
tretinoin, and alpha-estradiol) as having significant posi-
tive connectivity with the estrogen signature; and 5 com-
pounds (trichostatin A, fulvestrant, LY-294002, vorinos-
tat, and geldanamycin) that had significant negative con-
nectivity.
With our new connectivity map set-level analysis 16
compounds were found to have significant positive con-
nection, and 25 compounds had significant negative
connection to the estrogen gene signature. The 16
compounds with positive connection included genistein,
estradiol, and alpha-estradiol, all known to be estrogen
receptor agonists. The 25 compounds with negative con-
nection included fulvestrant, raloxifene and tamoxifen,
all known to be estrogen receptor antagonists. In com-
parison, the Lamb method identified all the estrogen re-
ceptor agonists above, but missed all the estrogen recep-
tor antagonists except fulvestrant. These results there-
fore indicate the sensitivity of our new method is substan-
tially increased. The Lamb method was able to detect the
pure estrogen receptor antagonist fulvestrant, but missed
the two compounds tamoxifen and raloxifene which have
mixed antagonist and agonist estrogen receptor activi-
ties.
The results from our set level analysis also suggest
that nordihydroguaiaretic acid (NDGA) has significant
positive connection with estradiol. This connection is
supported by recent studies [6, 7], where NDGA has
been shown to have estrogenic activity and able to elicit
an estrogen-like response. Another compound monor-
den (radicicol), suggested by our method as having neg-
ative connection to the estrogen gene signature, has been
shown to repress the transcriptional function of the es-
trogen receptor [8] which suggests that it may have some
estrogen receptor antagonist-like properties. The tabu-
lated results of querying both connectivity maps using
the estrogen gene signature are included in the supple-
mentary data. Fig.2 summarizes the numbers of signif-
icant connections identified by both connectivity maps.
All 9 compounds found significant by Lamb et al’s Con-
nectivity Map were also identified by the new method
(either on the instance level or on the set level or both).
However many compounds identified as significant with
either positive or negative connection to estradiol using
our method were not identified by Lamb et al’s Con-
nectivity Map, included amongst these were raloxifene,
7FIG. 2: Estrogen gene signature: The Venn diagram sum-
marizing the findings of significant connections as identified
by Lamb et al’s Connectivity Map and the new method here.
The labelling follows the same conventions as in the previous
figure.
tamoxifen, monorden, and NDGA.
3. Immunosuppressive therapy
For further testing we compiled a new gene signature
from a study on cardiac allograft rejection and response
to immunosuppressive therapy [9], where patients were
treated with standard immunosuppression with corticos-
teroids, antimetabolites, calcineurin inhibitors, and/or
sirolimus. This gene signature consisted of 40 Affymetrix
probe set IDs (see Table 2 of [9]). Our set-level analy-
sis identified 29 compounds as having significant connec-
tions with this gene signature. The three top compounds
were azathioprine, thalidomide, and rosiglitazone. Aza-
thioprine is a commonly used immunosuppressive drug
[10, 11], so its significant positive connection with the
gene signature is a good indication that our new connec-
tivity map works very well here. The second compound
thalidomide, which had a positive connection score, also
has known immunosuppressive activities [12], inhibits re-
lease of TNFα from monocytes, and modulates other
cytokine actions. The recognized properties of these
molecules therefore accord with the outcome of the con-
nectivity matching. The third compound rosiglitazone
had a negative connection with the signature suggesting
it may have properties to reduce or mitigate the effects of
immunosuppressive activity. Recently, rosiglitazone was
reported to suppress cyclosporin-induced chronic trans-
plant dysfunction and prolong survival of rat cardiac al-
lografts (Chen et al, 2007, Transplantation) , where cy-
closporin is also a commonly used immunosuppressive
drug [14].
At the instance level, our method identified 89 ref-
erence profiles as having significant connections to the
immunosuppressive drug gene signature, representing 63
distinct compounds. The top 3 compounds were aza-
thioprine, staurosporine, and trichostatin A, which all
achieved positive connection scores with this gene sig-
nature. The second compound, staurosporine, a pro-
tein kinase C inhibitor, is classified as an antineoplastic
and immunosuppressive antibiotic drug [15]. The third
compound, trichostatin A, was recently shown to have
some immunosuppressive effects in leukemia T cells [16].
Therefore the method of instance testing could be partic-
ularly valuable for the identification of pharmacological
and toxicological properties in novel molecules.
IV. DISCUSSION
We have presented in this paper a new framework for
a connectivity map, with the advantages that statistical
significance measures are calculated at both treatment
instance level and treatment set level, thus providing ef-
fective control over false connections. This important
safeguard was not available in Lamb et al’s Connectiv-
ity Map at the instance level, as revealed by the two
examples of random gene signatures. As the connectiv-
ity maps are most useful for high throughput screening
and for generating new biological hypothesis, it is crucial
that false connections are tightly controlled, such that
the users do not end up chasing false connections and
wasting time and money. We compared the performance
of Lamb et al’s Connectivity Map and the new method
presented in this paper, using two gene signatures com-
piled by Lamb et al and also a new gene signature for
immunosuppressive drugs. All these examples demon-
strated that our new method is more sensitive and gives
more robust results than Lamb et al’s method.
The set-level analysis of Lamb et al’s Connectivity Map
tests an implicit null hypothesis that is not most appro-
priate. This can be seen more clearly from recent studies
on the significance analysis of gene sets [17, 18]. Tian et
al were among the first groups of authors who made ex-
plicit distinctions between two null hypotheses [17] con-
cerning a set of entities ( a set of genes in context of Tian
et al’s paper). In the present context of connectivity map,
the two null hypotheses are:
1. Hypothesis Q1: The treatment instances in a set
show the same pattern of connections with the query
gene signature compared with the rest of the treatment
instances.
2. Hypothesis Q2: The treatment set does not contain
any treatment instances which have real connections with
the query gene signature.
Tian et al’s discussions over the relationship between
Q1 and Q2 [17] apply to a treatment set as follows: Given
all the 453 treatment instances, even if none of them have
real connection to the query gene signature, the observed
connection scores of a treatment set could still be very
different from those treatment instances outside of the
set because of the special correlation structure among the
treatment instances within the set. Chen et al also raised
some concerns with testing the hypothesisQ1 (Chen et al,
2007, Bioinformatics), that this hypothesis does not test
8whether the treatment set has above-random connections
to the query gene signature, but rather it tests whether
the observed connections in the set are more or less than
a randomly formed set of same size. We agree with Chen
et al’s assessment on the inappropriateness of Q1. It was
clear that Lamb et al’s Connectivity Map was testing
the null hypothesis Q1. Here we tested Q2 which is more
appropriate.
Our results indicate that the method presented here
can identify many significant connections to a query gene
signature. Then what criteria should we use and which
compounds should we choose if new biological hypothe-
ses are to be developed? Our suggestion is to concentrate
more on those compounds which have many replicate in-
stances in the connectivity map. Because the results ob-
tained for those big treatment sets do not depend heavily
on the quality of a small number of treatment instances,
as in the case of small treatment sets or singleton sets
(treatment sets with only 1 instance each). Lamb et al
also recognized the importance of having replicate in-
stances, and noted that the power to detect connections
might be greater for compounds with many replicates.
In defining a treatment set, ideally only the treatment
instances of the same compound with the same dose and
the same cell type should be considered as a set. For
example, the biological state of HL60 cells perturbed by
raloxifene should be considered as a different biological
state from that of MCF7 cells perturbed with the same
raloxifene, thus these two instances of raloxifene should
not be put into the same set. In this paper for compar-
ison purpose we adopted Lamb et al’s choice in defining
a treatment set, i.e., all the instances of a compounds
were grouped together as a set regardless of their possi-
ble differences in dose or cell type. Mixing the instances
of a compound with different doses and/or different cell
types increases the heterogeneity of an otherwise more
homogenous treatment set. This tends to average out
the distinct characteristics attributable to the cell type or
dosage difference, making some set-level connections in-
significant or their interpretation difficult. In such cases
the instance level connections supported by statistical
significance can be of great help in interpreting the re-
sults. For future connectivity maps, efforts should be
made to provide as many more replicate treatment in-
stances (replicates with the same compound, the same
dose, and the same cell type, etc) so that the undesirable
reliance on individual instances can be minimized.
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